A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression
J Clin Psychiatry 2006;67(5):798-806
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Olanzapine-fluoxetine combination
has shown efficacy in the acute treatment of depressive
episodes in patients with bipolar I disorder. The
present analyses examined the efficacy and safety of
longer term treatment with olanzapine-fluoxetine
combination or olanzapine monotherapy in a 6-month
open-label extension study.
Method: 376 patients with DSM-IV bipolar I
disorder, depressed, who completed an acute trial
entered the open-label study and received 1 week of
olanzapine monotherapy (5-20 mg/day). At all subsequent
visits, patients could choose between olanzapine
monotherapy or olanzapine-fluoxetine combination (6/25, 6/50, or
12/50 mg/day). Three treatment groups were defined
retrospectively according to the medication course
taken from week 1: olanzapine, olanzapine-fluoxetine
combination, or switched. The efficacy measures were
the Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions-Bipolar
Version, and Young Mania Rating Scale. The study
was conducted from July 2000 to May 2002.
Results: Among patients who started in
remission, MADRS total scores did not change significantly
from baseline to endpoint in the olanzapine-fluoxetine
combination (0.8) or olanzapine (0.3) groups, but
increased slightly in the switched (2.3, p = .02) group. For
patients who started in nonremission, MADRS total scores
decreased significantly in all groups (olanzapine-fluoxetine combination: - 5.7, p = .001; olanzapine:
- 11.6, p = .004; switched: - 6.4, p = .015). The majority of
patients who entered the study in nonremission
achieved remission (MADRS total score < = 12) during the
trial (olanzapine - fluoxetine combination: 66.7%,
olanzapine: 64.7%, switched: 62.5%). The overall rate of
depressive relapse was 27.4%, and the overall incidence of
mania emergence was 5.9%.
Conclusions: The present findings suggest that
long-term treatment with olanzapine-fluoxetine
combination may be a useful option for the management of
depressive symptoms and carries a low risk of mania